Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines

作者：Horwitz Steven M^*; Zelenetz Andrew D; Gordon Leo I; Wierda William G; Abramson Jeremy S; Advani Ranjana H; Andreadis C Babis; Bartlett Nancy; Byrd John C; Fayad Luis E; Fisher Richard I; Glenn Martha J; Habermann Thomas M; Harris Nancy Lee; Hernandez Ilizaliturri Francisco; Hoppe Richard T; Kaminski Mark S; Kelsey Christopher R; Kim Youn H; Krivacic Susan; LaCasce Ann S; Lunning Matthew; Nademanee Auay****; Press Oliver; Rabinovitch Rachel

来源：Journal of the National Comprehensive Cancer Network, 2016, 14(9): 1067-1079.

Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.

• 出版日期2016-9
• 单位西北大学